Antiproliferative_JJ effect_NN in_IN chronic_JJ myeloid_JJ leukaemia_NN cells_NNS by_IN antisense_NN peptide_NN nucleic_JJ acids_NNS Peptide_NN nucleic_JJ acid_NN (_( PNA_NP )_) is_VBZ a_DT synthetic_JJ DNA_NN analogue_NN that_WDT is_VBZ resistant_JJ to_TO nucleases_NNS and_CC proteases_NNS and_CC binds_NNS with_IN exceptional_JJ affinity_NN to_TO RNA_NP ._SENT Because_IN of_IN these_DT properties_NNS PNA_NP has_VBZ the_DT potential_NN to_TO become_VB a_DT powerful_JJ therapeutic_JJ agent_NN to_TO be_VB used_VBN in_IN vivo_RB ._SENT Until_IN now_RB ,_, however_RB ,_, the_DT use_NN of_IN PNA_NP in_IN vivo_RB has_VBZ not_RB been_VBN much_RB investigated_VBN ._SENT Here_RB ,_, we_PP have_VBP attempted_VBN to_TO reduce_VB the_DT expression_NN of_IN the_DT bcr_NN /abl_NN oncogene_NN in_IN chronic_JJ myeloid_JJ leukaemia_NN KYO-1_NP cells_NNS using_VBG a_DT 13mer_NP PNA_NP sequence_NN (_( asPNA_NN )_) designed_VBN to_TO hybridise_VB to_TO the_DT b2a2_JJ junction_NN of_IN bcr_NN /abl_NN mRNA_NN ._SENT To_TO enhance_VB cellular_JJ uptake_NN asPNA_NN was_VBD covalently_RB linked_VBN to_TO the_DT basic_JJ peptide_NN VKRKKKP_NP (_( NLS-asPNA_NP )_) ._SENT Moreover_RB ,_, to_TO investigate_VB the_DT cellular_JJ uptake_NN by_IN confocal_JJ microscopy_NN ,_, both_CC PNAs_NP were_VBD linked_VBN by_IN their_PP$ N-terminus_NN to_TO fluorescein_NN (_( FL_NP )_) ._SENT Studies_NNS of_IN uptake_NN ,_, carried_VBD out_RP at_IN 4_CD and_CC 37C_JJ on_IN living_VBG KYO-1_NP cells_NNS stained_VBN with_IN hexidium_NN iodide_NN ,_, showed_VBD that_IN both_DT NLS-asPNA-FL_NN and_CC asPNA-FL_NN were_VBD taken_VBN up_RP by_IN the_DT cells_NNS ,_, through_IN a_DT receptor-independent_JJ mechanism_NN ._SENT The_DT intracellular_JJ amount_NN of_IN NLS-asPNA-FL_NP was_VBD about_RB two_CD to_TO three_CD times_NNS higher_JJR than_IN that_IN of_IN asPNA-FL_NN ._SENT Using_VBG a_DT semi-quantitative_JJ RT_NP --_: PCR_NP technique_NN we_PP found_VBD that_IN 10_CD microM_NP asPNA_NP and_CC NLS-asPNA_NP reduced_VBD the_DT level_NN of_IN b2a2_JJ mRNA_NN in_IN KYO-1_NP cells_NNS to_TO 20_CD +-_NN 5_CD %_NN and_CC 60_CD +-_NN 10_CD %_NN of_IN the_DT control_NN ,_, respectively_RB ._SENT Western_JJ blot_NN analysis_NN showed_VBD that_IN asPNA_NP promoted_VBD a_DT significant_JJ inhibition_NN of_IN p210BCR_NN /ABL_NN protein_NN :_: residual_JJ protein_NN measured_VBN in_IN cells_NNS exposed_VBN for_IN 48_CD h_NN to_TO asPNA_NN was_VBD similar35_JJ %_NN of_IN the_DT control_NN ._SENT Additionally_RB ,_, asPNA_NP impaired_JJ cell_NN growth_NN to_TO 50_CD +-_NN 5_CD %_NN of_IN the_DT control_NN and_CC inhibited_VBD completion_NN of_IN the_DT cell_NN cycle_NN ._SENT In_IN summary_NN ,_, these_DT results_NNS demonstrate_VBP that_IN a_DT PNA_NP 13mer_NP is_VBZ taken_VBN up_RP by_IN KYO-1_NP cells_NNS and_CC is_VBZ capable_JJ of_IN producing_VBG a_DT significant_JJ and_CC specific_JJ down-regulation_NN of_IN the_DT bcr_NN /abl_NN oncogene_NN involved_VBN in_IN leukaemogenesis_NN ._SENT Over_IN the_DT past_JJ few_JJ years_NNS ,_, peptide_NN nucleic_JJ acids_NNS (_( PNAs_NP )_) have_VBP emerged_VBN as_IN one_CD of_IN the_DT most_RBS promising_JJ new_JJ types_NNS of_IN therapeutic_JJ oligonucleotides_NNS in_IN the_DT form_NN of_IN antisense_NN and_CC anti-gene_NN molecules_NNS ._SENT From_IN the_DT chemical_JJ point_NN of_IN view_NN ,_, PNA_NP is_VBZ both_CC a_DT peptide_NN and_CC a_DT nucleic_JJ acid_NN ,_, since_IN it_PP is_VBZ a_DT hybrid_JJ molecule_NN consisting_VBG of_IN N-(2-aminoethyl)glycine_JJ monomers_NNS linked_VBN by_IN amide_NN bonds_NNS (_( ,_, )_) ._SENT The_DT purine_NN (_( A_NP and_CC G_NP )_) and_CC pyrimidine_NN (_( C_NP and_CC T_NN )_) nucleobases_NNS are_VBP attached_VBN to_TO this_DT polyamide_NN backbone_NN via_IN a_DT methylene_NN carbonyl_NN linkage_NN ._SENT As_IN PNAs_NP are_VBP not_RB charged_VBN at_IN physiological_JJ pH_NN ,_, they_PP bind_VBP to_TO complementary_JJ nucleic_JJ acid_NN strands_NNS with_IN higher_JJR affinity_NN than_IN do_VB natural_JJ nucleic_JJ acids_NNS ._SENT Although_IN hybridisation_NN of_IN PNAs_NP to_TO complementary_JJ DNA_NP and_CC RNA_NP obeys_VBZ the_DT Watson_NP --_: Crick_NP rules_NNS ,_, both_CC parallel_JJ and_CC antiparallel_JJ duplexes_NNS can_MD be_VB formed_VBN ._SENT The_DT N-terminus_NP corresponds_VBZ to_TO the_DT 5_CD '_POS end_NN and_CC the_DT C-terminus_NP to_TO the_DT 3_CD '_POS end_NN of_IN a_DT normal_JJ oligonucleotide_NN (_( --_: )_) ._SENT However_RB ,_, antiparallel_JJ PNA_NP --_: DNA_NP and_CC PNA_NP --_: RNA_NP duplexes_NNS are_VBP more_RBR stable_JJ and_CC form_VB more_RBR rapidly_RB than_IN the_DT corresponding_JJ parallel_JJ duplexes_NNS ._SENT The_DT PNA_NP sequences_NNS used_VBN in_IN this_DT study_NN are_VBP shown_VBN in_IN Figure_NP ._SENT They_PP are_VBP designed_VBN to_TO reduce_VB the_DT expression_NN of_IN the_DT bcr_NN /abl_NN oncogene_NN in_IN chronic_JJ myelogenous_JJ leukaemia_NN (_( CML_NP )_) cells_NNS (_( --_: )_) ._SENT In_IN most_JJS CML_NP patients_NNS ,_, leukaemic_JJ cells_NNS contain_VBP the_DT Philadelphia_NP (_( Ph_NN )_) chromosome_NN ,_, which_WDT derives_VBZ from_IN a_DT reciprocal_JJ translocation_NN of_IN chromosomes_NNS 9q_JJ and_CC 22q_JJ ._SENT Such_PDT a_DT translocation_NN generates_VBZ a_DT fused_VBN bcr_NN /abl_NN oncogene_NN (_( with_IN either_CC a_DT b2a2_JJ or_CC b3a2_JJ junction_NN )_) encoding_VBG a_DT protein_NN of_IN 210_CD kDa_NN (_( p210BCR_NN /ABL_NN )_) which_WDT is_VBZ involved_VBN in_IN leukaemogenesis_NN (_( ,_, )_) ._SENT Protein_NN p210BCR_NN /ABL_NN has_VBZ a_DT higher_JJR tyrosine_NN phosphokinase_NN activity_NN than_IN the_DT normal_JJ ABL_NP protein_NN and_CC its_PP$ structure_NN allows_VBZ multiple_JJ protein_NN --_: protein_NN interactions_NNS that_WDT link_VBP p210BCR_NN /ABL_NN to_TO several_JJ intracellular_JJ pathways_NNS ,_, including_VBG the_DT ras_JJ pathway_NN ,_, which_WDT regulates_VBZ cell_NN proliferation_NN and_CC differentiation_NN (_( --_: )_) ._SENT The_DT presence_NN of_IN a_DT unique_JJ sequence_NN at_IN b2a2_JJ and_CC b3a2_JJ mRNA_NN junctions_NNS and_CC the_DT observation_NN that_IN CML_NP cells_NNS require_VBP p210BCR_NN /ABL_NN to_TO survive_VB make_VB the_DT bcr_NN /abl_NN gene_NN an_DT attractive_JJ target_NN for_IN antisense_NN molecules_NNS ._SENT Attempts_NNS to_TO reduce_VB the_DT intracellular_JJ level_NN of_IN bcr_NN /abl_NN mRNA_NN in_IN different_JJ cell_NN lines_NNS by_IN means_NNS of_IN antisense_NN oligonucleotides_NNS have_VBP been_VBN reported_VBN ._SENT However_RB ,_, the_DT results_NNS have_VBP not_RB been_VBN very_RB satisfactory_JJ ,_, because_IN normal_JJ and_CC thioate_JJ antisense_NN oligonucleotides_NNS displayed_VBD a_DT number_NN of_IN limits_NNS ,_, including_VBG nuclease_NN degradation_NN ,_, non-specific_JJ effects_NNS and_CC insufficient_JJ target_NN affinity_NN ._SENT PNAs_NNS are_VBP not_RB susceptible_JJ to_TO degradation_NN by_IN endogenous_JJ nucleases_NNS and_CC proteases_NNS and_CC bind_NN to_TO RNA_NP targets_NNS with_IN exceptionally_RB high_JJ affinity_NN and_CC in_IN a_DT sequence-specific_JJ manner_NN ._SENT Because_IN of_IN these_DT favourable_JJ properties_NNS ,_, PNAs_NNS are_VBP potentially_RB more_RBR powerful_JJ antisense_NN agents_NNS than_IN phosphorothioate_NN oligonucleotides_NNS ._SENT To_TO date_NN ,_, only_RB a_DT few_JJ reports_NNS have_VBP shown_VBN that_IN PNAs_NP ,_, either_DT free_JJ or_CC conjugated_JJ ,_, produce_VB an_DT antisense_NN or_CC antigene_NN effect_NN in_IN vivo_JJ (_( --_: )_) ._SENT In_IN the_DT study_NN presented_VBD herein_RB we_PP have_VBP explored_VBN the_DT capacity_NN of_IN 13mer_JJ antisense_NN PNAs_NNS to_TO inhibit_VB the_DT expression_NN of_IN bcr_NN /abl_NN in_IN leukaemic_JJ KYO-1_NP cells_NNS ._SENT The_DT PNAs_NP were_VBD designed_VBN to_TO bind_VB to_TO the_DT b2a2_JJ junction_NN of_IN bcr_NN /abl_NN mRNA_NN and_CC thus_RB block_VB its_PP$ translation_NN sterically_RB ._SENT We_PP found_VBD that_IN the_DT designed_VBN b2a2_NN antisense_NN PNAs_NP :_: (_( i_NP )_) are_VBP taken_VBN up_RP by_IN KYO-1_NP cells_NNS ;_: (_( ii_NNS )_) specifically_RB reduce_VB the_DT level_NN of_IN p210BCR_NN /ABL_NN ;_: (_( iii_NNS )_) inhibit_VBP completion_NN of_IN the_DT cell_NN cycle_NN ;_: (_( iv_NN )_) impair_VB cell_NN growth_NN to_TO 50_CD %_NN of_IN the_DT control_NN ._SENT Figure_NP 1_CD |_SYM Sequence_NN of_IN the_DT b2a2_JJ junction_NN of_IN bcr_NN /abl_NN mRNA_NN expressed_VBN in_IN KYO-1_NP cells_NNS ._SENT Sequence_NN of_IN the_DT b2a2_JJ junction_NN of_IN bcr_NN /abl_NN mRNA_NN expressed_VBN in_IN KYO-1_NP cells_NNS ._SENT The_DT structures_NNS of_IN the_DT antisense_NN and_CC control_NN PNAs_NNS used_VBN in_IN this_DT study_NN are_VBP also_RB shown_VBN ._SENT PNA_NP synthesis_NN |_SYM The_DT PNAs_NNS used_VBN in_IN this_DT study_NN were_VBD made_VBN by_IN solid_JJ phase_NN synthesis_NN using_VBG a_DT peptide_NN synthesiser_NN (_( Applied_NP Biosystems_NP 433A_NP peptide_NN synthesiser_NN )_) and_CC PNA_NP synthesiser_NP (_( Perspective_NP Biosystems_NP Expedite_NP Nucleic_NP Acid_NP Synthesis_NP System_NP )_) ._SENT All_DT solvents_NNS (_( Biosolve_NP )_) were_VBD used_VBN as_IN received_VBN ._SENT The_DT solid_JJ phase_NN syntheses_NNS were_VBD performed_VBN on_IN PEG-PS_NP beads_NNS as_IN solid_JJ support_NN with_IN rink-amide_NN as_IN linker_NN (_( loading_VBG 0.17_CD micromol_NN /mg_NN )_) ._SENT For_IN PNAs_NP conjugated_VBD to_TO NLS_NP ,_, first_RB the_DT peptide_NN part_NN was_VBD assembled_VBN on_IN the_DT peptide_NN synthesiser_NN on_IN the_DT 20_CD micromol_NN scale_NN using_VBG protected_JJ amino_NN acids_NNS [_SYM 5_CD equivalents_NNS ,_, Fmoc-Val-OH_NP ,_, Fmoc-Lys(Boc)-OH_NP ,_, Fmoc-Arg(Pbf)-OH_NP and_CC Fmoc-Pro-OH_NP ]_SYM under_IN the_DT agency_NN of_IN BOP_NP /HOBt_NN as_IN the_DT coupling_NN agent_NN ._SENT Only_RB the_DT first_JJ coupling_NN ,_, that_WDT of_IN valine_NN ,_, was_VBD double_JJ ,_, and_CC after_IN the_DT synthesis_NN was_VBD complete_JJ the_DT final_JJ Fmoc_NP was_VBD left_VBN on_RP ._SENT The_DT loading_NN was_VBD determined_VBN by_IN deprotection_NN of_IN a_DT small_JJ amount_NN of_IN the_DT resin_NN and_CC measuring_VBG the_DT absorbance_NN of_IN the_DT liberated_JJ Fmoc_NP protecting_VBG group_NN (_( loading_VBG 0.13_CD micromol_NN /mg_NN ,_, efficiency_NN 98_CD %_NN )_) ._SENT Assembly_NN of_IN the_DT PNAs_NP was_VBD established_VBN using_VBG the_DT standard_JJ protocol_NN described_VBN in_IN the_DT synthesiser_NN manual_NN ,_, on_IN the_DT 2_CD micromol_NN scale_NN using_VBG Fmoc_NP chemistry_NN and_CC monomers_NNS in_IN which_WDT the_DT exocyclic_JJ amines_NNS were_VBD Bhoc_NN protected_VBN (_( Perspective_NP Biosystems_NP )_) ._SENT As_IN solid_JJ support_NN either_CC PRG-PS_NN beads_NNS with_IN rink-amide_NN as_IN the_DT linker_NN (_( loading_VBG 0.17_CD micromol_NN /mg_NN )_) or_CC NLS-functionalised_JJ resin_NN (_( loading_VBG 0.13_CD micromol_NN /mg_NN )_) was_VBD used_VBN ._SENT After_IN removal_NN of_IN the_DT final_JJ Fmoc_NP protecting_VBG group_NN the_DT oligomer_NN was_VBD either_RB cleaved_VBN from_IN the_DT resin_NN and_CC deprotected_JJ under_IN acidic_JJ conditions_NNS (_( TFA_NP /TIS_NP /_SYM H2O_NP ,_, 9:1:1_CD v_NN /v_NP /v_NP )_) or_CC first_RB coupled_VBN twice_RB with_IN the_DT O-linker_NN [_SYM FmocHN(CH2)2O(CH2)OCH2CO2H_NP ]_SYM ,_, then_RB reacted_VBN with_IN 5(6)-carboxyfluorescein_NP succinimide_NN ester_NN (_( Molecular_NP Probes_NP )_) and_CC subsequently_RB cleaved_VBN with_IN concomitant_JJ deprotection_NN ._SENT RP-HPLC_NN purification_NN and_CC analysis_NN were_VBD carried_VBN out_RP on_IN a_DT JASCO_NP HPLC_NP system_NN equipped_VBN with_IN an_DT Altima_NP C18_NP column_NN (_( 10_CD x_SYM 250_CD mm_NN )_) ._SENT Gradient_JJ elution_NN was_VBD performed_VBN at_IN 40C_JJ by_IN building_VBG up_RP a_DT gradient_JJ starting_NN with_IN buffer_NN A_NP (_( 0.1_CD %_NN TFA_NP in_IN water_NN )_) and_CC applying_VBG buffer_NN B_NN (_( 0.1_CD %_NN TFA_NP in_IN acetonitrile_JJ /water_NN ,_, 3:1_CD v_NN /v_NN )_) with_IN a_DT flow_NN rate_NN of_IN 4_CD ml_NN /min_NN ._SENT The_DT PNAs_NP obtained_VBD were_VBD lyophilised_VBN and_CC characterised_VBN by_IN matrix-assisted_JJ laser_NN desorption_NN /ionisation_NN time-of-flight_NN mass_NN spectrometry_NN (_( MALDI-TOF_NP MS_NP )_) and_CC RP-HPLC_NP ._SENT Cell_NN cultures_NNS |_SYM CML_NP cell_NN lines_NNS K562_NN (_( a_DT gift_NN of_IN Dr_NP M._NP Giunta_NP ,_, Bone_NP Marrow_NP Transplantation_NP Unit_NP ,_, Medical_NP School_NP ,_, University_NP of_IN Udine_NP ,_, Italy_NP )_) and_CC KYO-1_NP (_( a_DT gift_NN of_IN Dr_NP C._NP M._NP Broughton_NP ,_, Department_NP of_IN Hematology_NP ,_, University_NP of_IN Liverpool_NP ,_, UK_NP )_) were_VBD maintained_VBN in_IN exponential_JJ growth_NN in_IN RPMI_NP 1640_CD medium_NN containing_VBG 100_CD U_NP /ml_NN penicillin_NN ,_, 100_CD mg_NN /ml_NN streptomycin_NN ,_, 200_CD mM_NP l-glutamine_NN and_CC 10_CD %_NN fetal_JJ bovine_JJ serum_NN (_( FBS_NP )_) (_( Celbio_NP ,_, Milan_NP ,_, Italy_NP )_) ,_, which_WDT was_VBD heat_NN inactivated_VBN at_IN 56C_NN for_IN 30_CD min_NN ._SENT Cell_NN cycle_NN analysis_NN |_SYM Cell_JJ cycle_NN analysis_NN was_VBD performed_VBN on_IN KYO-1_NP cells_NNS growing_VBG in_IN the_DT presence_NN of_IN 10_CD microM_NP PNA_NP for_IN 30_CD h._NP Briefly_NP ,_, KYO-1_NP cells_NNS were_VBD seeded_VBN in_IN a_DT 24-well_JJ plate_NN at_IN a_DT cell_NN density_NN of_IN 105_CD cells_NNS /ml_NN ,_, 24_CD h_NN before_IN PNA_NP treatment_NN ._SENT Cells_NNS (_( 2_CD x_SYM 105_CD )_) were_VBD harvested_VBN (_( 240_CD g_NN ,_, 4C_NP )_) ,_, resuspended_VBN in_IN 0.5_CD ml_NN of_IN PBS_NP and_CC washed_VBD twice_RB ._SENT While_IN vortexing_NN ,_, 1_CD ml_NN of_IN ice-cold_JJ 70_CD %_NN ethanol_NN was_VBD added_VBN dropwise_RB to_TO the_DT pellet_NN and_CC the_DT cells_NNS were_VBD allowed_VBN to_TO fix_VB overnight_JJ at_IN 4C_JJ ._SENT Prior_RB to_TO FACS_NP analysis_NN (_( Becton_NP Dickinson_NP )_) the_DT cells_NNS were_VBD stained_VBN with_IN a_DT solution_NN containing_VBG 0.05_CD mg_NN /ml_NN propidium_NN iodide_NN and_CC 0.5_CD mg_NN /ml_NN RNase_NP A._NP The_DT cells_NNS were_VBD centrifuged_VBN and_CC the_DT supernatant_JJ poured_VBD off_RP ._SENT The_DT cells_NNS were_VBD vortexed_VBN in_IN the_DT residual_JJ ethanol_NN and_CC then_RB 0.5_CD ml_NN of_IN propidium_NN iodide_NN was_VBD added_VBN to_TO each_DT sample_NN tube_NN ._SENT The_DT cells_NNS were_VBD incubated_VBN for_IN 30_CD min_NN at_IN 37C_JJ and_CC then_RB analysed_VBN by_IN FACS_NP ._SENT Proliferation_NN assay_NN in_IN liquid_JJ culture_NN |_SYM Aliquots_NP of_IN 2_CD x_SYM 104_CD exponentially_RB growing_VBG KYO-1_NP cells_NNS in_IN liquid_JJ culture_NN were_VBD seeded_VBN in_IN 200_CD microl_NN of_IN complete_JJ medium_NN in_IN 96-well_NN microtitre_NN plates_NNS and_CC treated_VBN with_IN the_DT PNAs_NP ._SENT The_DT PNAs_NP were_VBD added_VBN to_TO the_DT medium_JJ 24_CD h_NN after_IN seeding_VBG ._SENT Cellular_JJ growth_NN was_VBD measured_VBN at_IN 24_CD ,_, 48_CD and_CC 72_CD h_NN using_VBG 0.4_CD mg_NN /ml_NN 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium_JJ bromide_NN (_( MTT_NP )_) ._SENT The_DT absorbance_NN was_VBD read_VBN at_IN 540_CD and_CC 690_CD nm_NN using_VBG a_DT microtitre_NN plate_NN reader_NN (_( Titertek_NP Multiscan_NP MCC_NP ;_: Labsystems_NP )_) ._SENT The_DT data_NNS are_VBP expressed_VBN in_IN terms_NNS of_IN T_NN /C_NN (_( OD_NN of_IN PNA-treated_JJ cells_NNS /OD_NN of_IN control_NN cells_NNS )_) as_IN a_DT measure_NN of_IN cell_NN viability_NN and_CC survival_NN in_IN the_DT presence_NN of_IN test_NN PNAs_NNS ._SENT Confocal_JJ microscopy_NN |_SYM KYO-1_NP cells_NNS were_VBD seeded_VBN in_IN 12-well_NP plates_NNS at_IN a_DT density_NN of_IN 0.8_CD x_NN 105_CD cells_NNS in_IN 600_CD microl_NN of_IN RPMI_NP medium_NN supplemented_VBD with_IN 10_CD %_NN heat-inactivated_JJ FBS_NP ._SENT After_IN 24_CD h_NN the_DT cells_NNS were_VBD exposed_VBN for_IN a_DT certain_JJ time_NN to_TO fluorescein-labeled_JJ non-conjugated_JJ PNA_NP (_( asPNA-FL_NN )_) and_CC PNA_NP conjugated_VBD to_TO the_DT basic_JJ peptide_NN VKRKKKP_NP (_( NLS-asPNA-NLS_NP )_) ._SENT The_DT cells_NNS were_VBD centrifuged_VBN ,_, washed_VBN twice_RB with_IN PBS_NP ,_, spun_VBN on_IN a_DT glass_NN slide_NN and_CC fixed_VBN with_IN 3_CD %_NN paraformaldehyde_NN (_( PFA_NP )_) in_IN PBS_NP for_IN 20_CD min_NN ._SENT After_IN washing_VBG with_IN 0.1_CD M_NN glycine_NN ,_, containing_VBG 0.02_CD %_NN sodium_NN azide_NN in_IN PBS_NP ,_, to_TO remove_VB PFA_NP ,_, and_CC Triton_NP X-100_NP (_( 0.1_CD %_NN in_IN PBS_NP )_) ,_, the_DT cells_NNS were_VBD incubated_VBN with_IN 24_CD microg_NN /ml_NN propidium_NN iodide_NN and_CC 0.4_CD mg_NN /ml_NN RNase_NP A_NP for_IN 30_CD min_NN at_IN 37C_JJ in_IN order_NN to_TO stain_VB the_DT nuclei_NNS ._SENT Then_RB coverslips_NNS were_VBD mounted_VBN on_IN the_DT glass_NN slide_NN with_IN mowiol_NN 4-88_CD and_CC DABCO_NP (_( 2.5_CD %_NN )_) ._SENT The_DT cells_NNS were_VBD analysed_VBN using_VBG a_DT Leica_NP DM_NP IRBE_NP confocal_JJ imaging_NN system_NN ._SENT Diaphragm_NN and_CC fluorescence_NN detection_NN levels_NNS were_VBD adjusted_VBN to_TO minimise_VB any_DT interference_NN between_IN the_DT fluorescein_NN and_CC propidium_NN iodide_NN channels_NNS ._SENT Hexidium_NN iodide_NN (_( Molecular_NP Probes_NP )_) was_VBD dissolved_VBN in_IN DMSO_NP and_CC 10_CD mM_NP stock_NN solutions_NNS were_VBD stored_VBN at_IN --_: 20C_JJ ._SENT RNA_NP purification_NN and_CC reverse_JJ transcription_NN --_: polymerase_NN chain_NN reaction_NN (_( RT_NP --_: PCR_NP )_) analysis_NN |_SYM RNA_NP purification_NN ._SENT Total_JJ cellular_JJ RNA_NP was_VBD extracted_VBN from_IN K562_NP and_CC KYO-1_NP cells_NNS using_VBG RNAqueous-4_NP PCR_NP (_( Ambion_NP )_) ._SENT This_DT method_NN is_VBZ based_VBN on_IN cell_NN lysis_NN in_IN a_DT solution_NN containing_VBG guanidinium_NN thiocyanate_NN ._SENT The_DT RNA_NP precipitate_NN was_VBD treated_VBN with_IN ultrapure_NN DNase_NP I_NP to_TO remove_VB DNA_NN traces_NNS and_CC the_DT RNA_NP solutions_NNS were_VBD stored_VBN at_IN --_: 80C_JJ ._SENT cDNA_NN synthesis_NN ._SENT A_DT volume_NN of_IN 5_CD microl_NN of_IN RNA_NP solution_NN in_IN diethylpyrocarbonate_JJ (DEPC)-treated_JJ water_NN was_VBD heated_VBN at_IN 70C_NP and_CC placed_VBN in_IN ice_NN ._SENT The_DT solution_NN was_VBD added_VBN to_TO 16.6_CD microl_NN of_IN cDNA_JJ mix_NN [_SYM 10_CD microl_NN of_IN 5x_NN buffer_NN ,_, 5_CD microl_NN of_IN 0.1_CD M_NP DTT_NP (_( Life_NP Technologies_NP )_) ,_, 2_CD microl_NN of_IN a_DT 12.5_CD pmol_NN primer_NN AZ_NP (_( 5'-CCA_NP TTTTTGGTTTGGGCTTCA-3_NP '_'' ;_: MWG_NP Biotech_NP )_) ,_, 2_CD microl_NN of_IN a_DT 5_CD mM_NP solution_NN containing_VBG equimolar_JJ amounts_NNS of_IN dATP_NN ,_, dCTP_NN ,_, dGTP_NN and_CC dTTP_NN (_( Amersham_NP Pharmacia_NP Biotech_NP )_) ,_, 0.6_CD microl_NN of_IN 40_CD U_NP /ml_NP RNase_NP inhibitor_NN (_( Life_NP Technologies_NPS )_) and_CC 1_CD microl_NN of_IN 200_CD U_NP M-MLV_NP reverse_JJ transcriptase_NN (_( Life_NP Technologies_NPS )_) ]_SYM ._SENT The_DT reactions_NNS (_( 50_CD microl_NN /tube_NN )_) were_VBD incubated_VBN for_IN 1_CD h_NN at_IN 37C_JJ ._SENT As_IN a_DT negative_JJ control_NN the_DT reverse_JJ transcription_NN reaction_NN was_VBD performed_VBN with_IN 5_CD microl_NN of_IN DEPC-treated_JJ water_NN ._SENT The_DT cDNA_NN was_VBD stored_VBN at_IN --_: 20C_JJ ._SENT Polymerase_NN chain_NN reaction_NN ._SENT A_DT volume_NN of_IN 10_CD microl_NN of_IN cDNA_NN ,_, heated_VBN at_IN 95C_NN for_IN 5_CD min_NN ,_, was_VBD mixed_VBN with_IN 16.5_CD microl_NN of_IN BCR_NP /ABL_JJ mix_NN [_SYM 10_CD microl_NN of_IN 10x_NP Taq_NP polymerase_NN buffer_NN (_( Boehringer_NP )_) ,_, 3_CD microl_NN of_IN 25_CD mM_NP MgCl2_NP ,_, 2_CD microl_NN of_IN 12.5_CD pmol_NN /microl_NN primer_NN EA500_NP (_( 5'-TGTGATTATAGCCTAAGACCC-3_NP '_'' ;_: MWG_NP Biotech_NP )_) ,_, 2_CD microl_NN of_IN 12.5_CD pmol_NN /microl_NN primer_NN EA122_NP (_( 5'-GTTTCAG_NP AAGCTTCTCCCTG-3_NP '_'' ;_: MWG-Biotech_NP )_) ,_, 2_CD microl_NN of_IN 5_CD mM_NP dNTPs_NNS with_IN equimolar_JJ amounts_NNS of_IN dTTP_NN ,_, dCTP_NN ,_, dATP_NN and_CC dGTP_NN (_( Amersham_NP Pharmacia_NP Biotech_NP )_) ,_, 0.5_CD microl_NN of_IN 2.5_CD U_NP /ml_NN AmpliTaq_NP DNA_NP polymerase_NN (_( Perkin_NP Elmer_NP )_) ]_SYM ._SENT Amplification_NN was_VBD carried_VBN out_RP on_IN an_DT automated_JJ DNA_NN thermal_JJ cycler_NN (_( Progene_NP )_) as_RB follows_VBZ :_: 35_CD cycles_NNS of_IN denaturation_NN (_( 94C_NN for_IN 30_CD s_NNS )_) ,_, annealing_VBG (_( 60C_JJ for_IN 30_CD s_NNS )_) and_CC extension_NN (_( 72C_NP for_IN 30_CD s_NNS )_) ._SENT Abl_NN amplification_NN (_( annealing_VBG at_IN 55C_NN )_) was_VBD carried_VBN out_RP with_IN primers_NNS EA500_NP and_CC ABL1A_NP (_( 5'-CCTCTCGCTGGA_NP CCCAGTGA_NP )_) ._SENT Two_CD positive_JJ cDNA_NN controls_NNS were_VBD used_VBN ._SENT First_RB ,_, RNA_NP extracted_VBD only_RB from_IN K562_NP cells_NNS was_VBD used_VBN to_TO amplify_VB the_DT b3a2bcr_NN /abl_NN mRNA_NN ._SENT Secondly_RB ,_, the_DT RNA_NP extracted_VBD only_RB from_IN KYO-1_NP cells_NNS was_VBD used_VBN to_TO amplify_VB the_DT b2a2bcr_NN /abl_NN mRNA_NN ._SENT Moreover_RB ,_, as_IN a_DT negative_JJ control_NN we_PP tried_VBD to_TO amplify_VB the_DT controls_NNS of_IN the_DT RNA_NP extraction_NN and_CC the_DT control_NN of_IN the_DT cDNA_NN reaction_NN ._SENT Western_JJ blots_NNS |_SYM Aliquots_NP of_IN 2_CD x_SYM 105_CD KYO-1_NP cells_NNS were_VBD lysed_VBN in_IN 2x_NP Laemmli_NP sample_NN buffer_NN (_( 3.3_CD %_NN SDS_NP ,_, 22_CD %_NN glycerol_NN ,_, 1.1_CD M_NP Tris_NP --_: HCl_NP ,_, pH_NN 6_CD ,_, 0.001_CD %_NN bromophenol_NN blue_JJ ,_, 10_CD %_NN beta-mercaptoethanol_NN )_) ._SENT Samples_NNS were_VBD heated_VBN at_IN 95C_NN for_IN 10_CD min_NN and_CC loaded_JJ (_( 70_CD microl_NN )_) in_IN either_DT 7_CD or_CC 12_CD %_NN resolving_VBG ,_, 5_CD %_NN stacking_VBG SDS_NP --_: polyacrylamide_NN gel_NN ._SENT Electrophoresis_NN was_VBD carried_VBN out_RP at_IN 100_CD and_CC 40_CD V_CD for_IN 45_CD min_NN and_CC 18_CD h_NN ,_, respectively_RB ._SENT The_DT relative_JJ concentration_NN of_IN the_DT protein_NN lysates_NNS was_VBD estimated_VBN electrophoretically_RB and_CC equal_JJ amounts_NNS of_IN lysates_NNS were_VBD transferred_VBN to_TO a_DT nitrocellulose_NN membrane_NN (_( Sartorius_NP )_) using_VBG a_DT Multiphor_NP II_NP Novablot_NP Transfer_NP Unit_NP (_( Amersham_NP Pharmacia_NP Biotech_NP )_) ._SENT The_DT membranes_NNS were_VBD then_RB cut_VBN at_IN the_DT 45_CD and_CC 210_CD kDa_NN molecular_JJ weight_NN levels_NNS ._SENT Both_DT membranes_NNS were_VBD used_VBN to_TO detect_VB the_DT BCR_NP /ABL_NN and_CC beta-actin_NN ._SENT A_DT double_JJ antibody_NN procedure_NN was_VBD used_VBN to_TO detect_VB the_DT proteins_NNS ._SENT The_DT membranes_NNS were_VBD incubated_VBN under_IN agitation_NN for_IN 1_CD h_NN at_IN room_NN temperature_NN in_IN blocking_VBG solution_NN (_( PBS_NP containing_VBG 5_CD %_NN dry_JJ milk_NN and_CC 0.1_CD %_NN Tween_NP 20_CD )_) ,_, then_RB at_IN room_NN temperature_NN for_IN 2_CD h_NN in_IN c-ABL_NP (_( Ab-3_NP )_) (_( 1:50_CD )_) and_CC beta-actin_NN monoclonal_NN antibodies_NNS (_( 1:20_CD 000_CD )_) (_( Calbiochem_NP )_) ._SENT The_DT antibody_NN solution_NN was_VBD removed_VBN and_CC the_DT membrane_NN was_VBD washed_VBN three_CD times_NNS with_IN PBS_NP containing_VBG 0.1_CD %_NN Tween_NP 20_CD ._SENT The_DT membranes_NNS were_VBD then_RB incubated_VBN (_( 1_CD h_NN at_IN room_NN temperature_NN under_IN agitation_NN )_) with_IN horseradish_NN peroxidase-conjugated_JJ goat_NN anti-mouse_NN IgG_NP (_( 1:1000_NP )_) (_( Sigma_NP )_) for_IN the_DT Ab-3_NP and_CC goat_NN anti-mouse_NN IgM_NP (_( 1:2000_NP )_) (_( Calbiochem_NP )_) for_IN the_DT beta-actin_NN antibody_NN ._SENT Chemiluminescence_NN was_VBD detected_VBN immediately_RB as_RB described_VBN by_IN the_DT manufacturer_NN (_( Super_NP Signal_NP West_NP Pico_NP Trial_NP ;_: Pierce_NP )_) ._SENT Films_NNS were_VBD exposed_VBN for_IN similar15_JJ min_NN for_IN BCR_NP /ABL_NN and_CC 1_CD min_NN for_IN beta-actin_NN ._SENT Target_NN and_CC antisense_NN PNA_NP molecules_NNS |_SYM Ph-positive_JJ KYO-1_NP cells_NNS express_VBP a_DT bcr_NN /abl_NN mRNA_NN which_WDT is_VBZ characterised_VBN by_IN a_DT bcr_NN exon_NN 2_CD /abl_NN exon_NN 2_CD (_( b2a2_NN )_) junction_NN ._SENT As_IN this_DT junction_NN is_VBZ a_DT unique_JJ sequence_NN in_IN CML_NP cells_NNS ,_, it_PP has_VBZ been_VBN chosen_VBN as_IN the_DT target_NN for_IN the_DT antisense_NN PNA_NN molecules_NNS used_VBN in_IN this_DT study_NN ._SENT According_VBG to_TO previous_JJ observations_NNS ,_, free_JJ PNAs_NNS do_VBP not_RB penetrate_VB or_CC hardly_RB penetrate_VB cell_NN membranes_NNS in_IN the_DT absence_NN of_IN a_DT specific_JJ carrier_NN (_( ,_, )_) ._SENT So_RB ,_, to_TO enhance_VB cellular_JJ uptake_NN ,_, the_DT designed_VBN antisense_NN PNA_NP was_VBD covalently_RB bound_VBN at_IN the_DT C-terminus_NP (_( 3_CD '_'' )_) to_TO a_DT short_JJ peptide_NN rich_JJ in_IN basic_JJ amino_NN acids_NNS ,_, having_VBG the_DT sequence_NN of_IN the_DT SV40_NP nuclear_JJ localisation_NN signal_NN peptide_NN (_( NLS_NP )_) (_( HO2C-VKRKKKP-NH2_NP )_) ._SENT Moreover_RB ,_, to_TO perform_VB uptake_NN studies_NNS by_IN flow_NN cytometry_NN and_CC confocal_JJ microscopy_NN ,_, both_CC free_JJ and_CC NLS-conjugated_JJ PNAs_NNS were_VBD covalently_RB linked_VBN at_IN their_PP$ N-terminus_NP (_( 5_CD '_'' )_) to_TO 5(6)-carboxyfluorescein_NP via_IN an_DT amide_NN bond_NN ._SENT The_DT PNA_NP 13mers_NP shown_VBN in_IN Figure_NN ,_, designed_VBN with_IN a_DT sequence_NN complementary_JJ to_TO the_DT bcr_NN /abl_NN mRNA_NN b2a2_NN junction_NN ,_, were_VBD assembled_VBN following_VBG a_DT well-established_JJ solid_JJ phase_NN protocol_NN ._SENT Sequential_JJ elongation_NN of_IN the_DT rink-amide-functionalised_JJ solid_JJ support_NN ,_, either_CC with_IN or_CC without_IN the_DT NLS_NP peptide_NN present_NN ,_, using_VBG Fmoc_NP /Bhoc-protected_JJ monomers_NNS under_IN the_DT agency_NN of_IN the_DT coupling_NN reagent_NN HATU_NP ,_, gave_VBD the_DT immobilised_VBN constructs_NNS ._SENT At_IN this_DT stage_NN ,_, the_DT label_NN could_MD be_VB introduced_VBN by_IN reacting_VBG the_DT deprotected_JJ N-terminus_NN with_IN the_DT succinimidyl_NN ester_NN of_IN 5(6)-carboxyfluorescein_NP ._SENT Removal_NN of_IN the_DT N-Bhoc_NP protecting_VBG groups_NNS and_CC concomitant_JJ release_NN of_IN the_DT support_NN was_VBD affected_VBN under_IN acidic_JJ conditions_NNS ,_, to_TO give_VB ,_, after_IN RP-HPLC_NP purification_NN ,_, the_DT PNA_NP conjugates_VBZ ._SENT The_DT homogeneity_NN and_CC identity_NN of_IN these_DT constructs_NNS were_VBD established_VBN by_IN RP-HPLC_NP and_CC MALDI-TOF_NP MS_NP ._SENT Antisense_NN PNA_NP oligomers_NNS were_VBD synthesised_VBN with_IN (_( NLS-asPNA_NP )_) and_CC without_IN (_( asPNA_NN )_) NLS_NP peptide_NN and_CC both_DT of_IN them_PP also_RB with_IN fluorescein_NN (_( asPNA-FL_NN and_CC NLS-asPNA-FL_NN )_) ._SENT As_IN a_DT control_NN we_PP designed_VBN parPNA_NN ,_, a_DT PNA_NP with_IN an_DT inverted_JJ sequence_NN compared_VBN to_TO asPNA_NN ,_, and_CC two_CD PNAs_NNS with_IN scrambled_JJ sequences_NNS ,_, scrPNA-1_JJ and_CC scrPNA-2_JJ ._SENT PNA_NP uptake_NN :_: confocal_JJ microscopy_NN and_CC FACS_NNS |_SYM It_PP has_VBZ recently_RB been_VBN reported_VBN that_IN unmodified_JJ ,_, carrier-free_JJ PNA_NP injected_VBD into_IN rats_NNS either_CC directly_RB into_IN the_DT brain_NN or_CC i.p._NN was_VBD able_JJ to_TO enter_VB neuronal_JJ cells_NNS and_CC specifically_RB reduce_VB gene_NN expression_NN ._SENT Other_JJ recent_JJ studies_NNS show_VBP that_IN unmodified_JJ antisense_NN PNA_NP molecules_NNS are_VBP taken_VBN up_RP by_IN protozoa_NNS (_( Entameba_NP hystolitica_NP )_) and_CC by_IN neurons_NNS in_IN culture_NN ._SENT These_DT data_NNS suggest_VBP that_IN a_DT certain_JJ amount_NN of_IN PNA_NP is_VBZ intrinsically_RB taken_VBN up_RP by_IN the_DT cells_NNS ,_, in_IN contrast_NN to_TO the_DT proposal_NN that_IN PNAs_NNS do_VBP not_RB pass_VB or_CC hardly_RB pass_VB through_IN the_DT membranes_NNS (_( ,_, --_: )_) ._SENT Thus_RB ,_, we_PP wished_VBD to_TO investigate_VB the_DT uptake_NN of_IN free_JJ asPNA-FL_NN and_CC peptide-conjugated_JJ NLS-asPNA-FL_NN by_IN KYO-1_NP cells_NNS using_VBG confocal_JJ microscopy_NN ._SENT Two_CD cell_NN staining_VBG procedures_NNS were_VBD followed_VBN ._SENT In_IN one_CD case_NN ,_, after_IN incubation_NN with_IN free_JJ asPNA-FL_NN or_CC NLS-asPNA-FL_NP ,_, the_DT cells_NNS were_VBD fixed_VBN on_IN a_DT glass_NN slide_NN and_CC exposed_VBD to_TO 0.1_CD %_NN Triton_NP X-100_NP and_CC propidium_NN iodide_NN ._SENT As_IN Triton_NP X-100_NP permeabilises_VBZ the_DT cell_NN membrane_NN ,_, it_PP is_VBZ possible_JJ that_IN some_DT of_IN the_DT PNA_NP taken_VBN up_RP by_IN the_DT cells_NNS is_VBZ lost_VBN during_IN the_DT washing_VBG steps_NNS ._SENT In_IN order_NN to_TO avoid_VB this_DT we_PP also_RB stained_VBD the_DT cells_NNS directly_RB ,_, i.e._FW without_IN fixing_VBG them_PP on_IN a_DT glass_NN plate_NN ,_, with_IN 3_CD microM_NN hexidium_NN iodide_NN ,_, a_DT dye_NN that_WDT binds_VBZ to_TO DNA_NP and_CC RNA_NP in_IN living_VBG cells_NNS and_CC displays_VBZ a_DT red_JJ fluorescence_NN ._SENT KYO-1_JJ cells_NNS were_VBD treated_VBN for_IN 2_CD h_NN with_IN hexidium_NN iodide_NN ,_, transferred_VBN to_TO growth_NN medium_NN containing_VBG either_DT free_JJ asPNA-FL_NN or_CC NLS-asPNA-FL_NN for_IN a_DT certain_JJ time_NN and_CC then_RB directly_RB analysed_VBN with_IN a_DT confocal_JJ microscope_NN ._SENT Figures_NNS A_NP and_CC B_NP and_CC show_NN images_NNS obtained_VBN by_IN both_DT staining_VBG methods_NNS ._SENT PNA-treated_NP KYO-1_NP cells_NNS fixed_VBN on_IN glass_NN and_CC stained_VBN with_IN propidium_NN iodide_NN are_VBP shown_VBN in_IN Figure_NP A._NP Figure_NP A_NP shows_VBZ the_DT nuclei_NNS of_IN KYO-1_NP cells_NNS stained_VBN in_IN red_NN by_IN propidium_NN iodide_NN ,_, while_IN Figure_NP B_NP shows_VBZ the_DT green_JJ fluorescent_JJ light_NN emitted_VBN by_IN asPNA-FL_NN (_( incubation_NN time_NN 24_CD h_NN )_) ._SENT It_PP is_VBZ clear_JJ from_IN these_DT pictures_NNS that_IN asPNA-FL_NN is_VBZ taken_VBN up_RP by_IN the_DT cells_NNS ._SENT A_DT superimposed_VBN view_NN of_IN Figure_NP A_NP and_CC B_NP is_VBZ reported_VBN in_IN Figure_NP C._NP This_DT image_NN clearly_RB shows_VBZ that_IN asPNA-FL_NN is_VBZ partly_RB located_VBN in_IN the_DT nuclei_NNS and_CC partly_RB in_IN the_DT cytoplasm_NN (_( green_JJ crown_NN surrounding_VBG the_DT nucleus_NN ,_, Fig._NN D_NN )_) ._SENT The_DT intracellular_JJ localisation_NN of_IN asPNA-FL_NN was_VBD also_RB confirmed_VBN by_IN xz-planes_NNS taken_VBN at_IN the_DT level_NN of_IN the_DT arrow_NN (_( Fig._NN E_NN )_) ._SENT The_DT uptake_NN of_IN NLS-asPNA-FL_NP by_IN KYO-1_NP cells_NNS is_VBZ shown_VBN in_IN Figure_NP B._NP NLS-asPNA-FL_NP is_VBZ localised_VBN in_IN both_CC the_DT cytoplasm_NN and_CC nucleus_NN ,_, where_WRB it_PP appears_VBZ mainly_RB confined_VBN to_TO the_DT nucleoli_NNS ._SENT Figure_NN shows_VBZ the_DT PNA_NP uptake_NN in_IN living_VBG KYO-1_NP cells_NNS stained_VBN with_IN hexidium_NN iodide_NN ._SENT The_DT images_NNS show_VBP in_IN an_DT unambiguous_JJ way_NN that_IN both_DT asPNA-FL_NN and_CC NLS-asPNA-FL_NP are_VBP taken_VBN up_RP by_IN the_DT cells_NNS ._SENT To_TO investigate_VB the_DT mechanism_NN by_IN which_WDT PNA_NP is_VBZ internalised_VBN in_IN KYO-1_NP cells_NNS ,_, experiments_NNS were_VBD performed_VBN at_IN 4C_JJ ._SENT Basically_RB ,_, the_DT cells_NNS were_VBD first_RB stained_VBN with_IN hexidium_NN iodide_NN ,_, cooled_VBN to_TO 4C_JJ over_IN 1_CD h_NN and_CC then_RB exposed_VBN to_TO 10_CD microM_NN asPNA-FL_NN or_CC NLS-asPNA-FL_NN for_IN a_DT further_JJR 5_CD h_NN at_IN 4C_JJ ._SENT After_IN incubation_NN the_DT cells_NNS were_VBD immediately_RB analysed_VBN with_IN a_DT confocal_JJ microscope_NN ._SENT We_PP observed_VBD that_IN both_DT free_JJ and_CC NLS-conjugated_JJ PNAs_NNS were_VBD also_RB detected_VBN in_IN the_DT cells_NNS at_IN low_JJ temperature_NN (_( not_RB shown_VBN )_) ._SENT An_DT estimate_NN of_IN the_DT fluorescence_NN intensity_NN associated_VBN with_IN the_DT KYO-1_NP cells_NNS treated_VBN with_IN asPNA-FL_NP and_CC NLS-asPNA-FL_NP was_VBD obtained_VBN by_IN flow_NN cytometry_NN ._SENT The_DT average_JJ fluorescence_NN intensity_NN associated_VBN with_IN the_DT cells_NNS treated_VBN with_IN 10_CD microM_NN asPNA-NLS-FL_NN was_VBD 210_CD +-_NN 20_CD units_NNS ,_, while_IN the_DT fluorescence_NN of_IN the_DT cells_NNS treated_VBN with_IN asPNA-FL_NN was_VBD about_RB three_CD times_NNS lower_RBR ,_, i.e._FW 70_CD +-_NN 15_CD units_NNS ._SENT These_DT values_NNS did_VBD not_RB significantly_RB change_VB over_IN incubation_NN periods_NNS up_RB to_TO 40_CD h._NN The_DT designed_VBN antisense_NN PNA_NP binds_VBZ the_DT b2a2_JJ mRNA_NN target_NN in_IN vitro_NP |_SYM In_IN order_NN to_TO demonstrate_VB that_IN the_DT designed_VBN antisense_NN PNAs_NNS stably_RB hybridise_VBP to_TO their_PP$ natural_JJ target_NN ,_, i.e._FW the_DT b2a2_JJ mRNA_NN junction_NN ,_, asPNA_NP ,_, asPNA-NLS_NNS ,_, parPNA_NN and_CC scrPNA_NN were_VBD incubated_VBN separately_RB with_IN total_JJ RNA_NP extracted_VBD from_IN KYO-1_NP cells_NNS ,_, at_IN concentrations_NNS increasing_VBG from_IN 1_CD to_TO 50_CD nM_NN ._SENT Both_DT asPNA_NP and_CC NLS-asPNA_NP are_VBP complementary_JJ to_TO a_DT 13mer_JJ stretch_NN of_IN the_DT b2a2_JJ junction_NN of_IN bcr_NN /abl_NN mRNA_NN ,_, with_IN which_WDT they_PP can_MD form_VB the_DT antiparallel_JJ PNA_NP --_: RNA_NP heteroduplex_NN shown_VBN in_IN Scheme_NP ,_, which_WDT could_MD sterically_RB block_VB reverse_JJ transcription_NN ._SENT In_IN contrast_NN ,_, parPNA_NN is_VBZ expected_VBN to_TO hybridize_VB to_TO the_DT b2a2_JJ junction_NN with_IN a_DT parallel_JJ orientation_NN ,_, forming_VBG a_DT PNA_NP --_: DNA_NN duplex_NN which_WDT is_VBZ expected_VBN to_TO be_VB less_RBR stable_JJ than_IN that_DT formed_VBN by_IN asPNA_NN (_( ,_, )_) ._SENT After_IN RT_NP --_: PCR_NP ,_, carried_VBD out_RP using_VBG the_DT primers_NNS EA122_NP and_CC EA500_NP ,_, the_DT reaction_NN products_NNS were_VBD separated_VBN by_IN polyacrylamide_NN electrophoresis_NN ._SENT It_PP can_MD be_VB seen_VBN that_IN asPNA_NN inhibits_VBZ reverse_JJ transcription_NN in_IN a_DT dose-dependent_JJ manner_NN ,_, completely_RB blocking_VBG the_DT enzymatic_JJ activity_NN at_IN a_DT concentration_NN as_IN low_JJ as_IN 50_CD nM_NN ._SENT Surprisingly_RB ,_, parPNA_NP too_RB showed_VBD a_DT remarkable_JJ ability_NN to_TO inhibit_VB reverse_JJ transcription_NN ,_, under_IN the_DT experimental_JJ conditions_NNS adopted_VBD ._SENT In_IN contrast_NN ,_, samples_NNS incubated_VBD either_RB in_IN the_DT absence_NN of_IN antisense_NN PNA_NP or_CC the_DT presence_NN of_IN srcPNA_NN (_( a_DT PNA_NP with_IN a_DT scrambled_JJ sequence_NN )_) did_VBD not_RB show_VB reverse_JJ transcription_NN inhibition_NN ._SENT The_DT efficiency_NN of_IN reverse_JJ transcriptase_NN was_VBD checked_VBN by_IN amplifying_VBG a_DT 128_CD nt_NN stretch_NN of_IN the_DT abl_NN gene_NN ,_, using_VBG primers_NNS ABL1A_NP and_CC EA500_NP ,_, in_IN each_DT reaction_NN tube_NN ._SENT It_PP can_MD be_VB seen_VBN that_IN in_IN all_DT samples_NNS the_DT expected_VBN abl_NN fragment_NN was_VBD obtained_VBN ._SENT These_DT results_NNS demonstrate_VBP that_IN the_DT designed_VBN antisense_NN PNAs_NNS are_VBP able_JJ to_TO bind_VB at_IN nanomolar_NN concentrations_NNS to_TO the_DT b2a2_JJ mRNA_NN junction_NN with_IN high_JJ affinity_NN and_CC completely_RB block_VB the_DT catalytic_JJ activity_NN of_IN reverse_JJ transcriptase_NN ._SENT We_PP also_RB performed_VBD RT_NP --_: PCR_NP experiments_NNS with_IN NLS-asPNA_NP and_CC have_VBP observed_VBN that_IN it_PP produces_VBZ an_DT inhibitory_JJ effect_NN roughly_RB similar_JJ to_TO that_DT obtained_VBN with_IN the_DT unconjugated_JJ asPNA_NN (_( not_RB shown_VBN )_) ._SENT The_DT thermodynamic_JJ stability_NN of_IN parallel_JJ and_CC antiparallel_JJ PNA_NP --_: RNA_NP hybrids_NNS was_VBD predicted_VBN using_VBG the_DT nearest_JJS neighbour_NN stacking_VBG energy_NN parameters_NNS reported_VBN by_IN Santa_NP Lucia_NP et_FW al._FW ,_, which_WDT allows_VBZ Tm_NP calculation_NN for_IN DNA_NP --_: DNA_NP duplexes_NNS ._SENT Taking_VBG into_IN account_NN that_IN PNA_NP --_: DNA_NP duplexes_NNS are_VBP more_RBR stable_JJ than_IN the_DT corresponding_JJ DNA_NN --_: DNA_NN duplexes_NNS by_IN similar1.0_JJ K_NP /base_NN and_CC that_DT PNA_NP --_: DNA_NP duplexes_NNS are_VBP less_RBR stable_JJ than_IN PNA_NP --_: RNA_NP by_IN similar4C_NN ,_, we_PP calculated_VBD for_IN the_DT antiparallel_JJ asPNA_NN --_: b2a2_JJ mRNA_NN heteroduplex_NN a_DT Tm_NN of_IN 68C_JJ at_IN 1_CD microM_NN ,_, 52C_NN at_IN 10_CD nM_NN and_CC 42C_JJ at_IN 10_CD pM_NN ._SENT As_RB for_IN the_DT parallel_JJ heteroduplex_NN formed_VBN by_IN parPNA_NN with_IN the_DT b2a2_JJ target_NN ,_, its_PP$ stability_NN should_MD be_VB comparable_JJ to_TO that_DT of_IN the_DT corresponding_JJ DNA_NN --_: DNA_NN duplex_NN ,_, i.e._FW 52C_NN at_IN 1_CD microM_NN ,_, 37C_JJ at_IN 10_CD nM_NN and_CC 26C_JJ at_IN 10_CD pM_NN (_( ,_, )_) ._SENT Antisense_NN PNA_NP binds_VBZ to_TO the_DT b2a2_JJ junction_NN in_IN vivo_JJ and_CC reduces_VBZ bcr_NN /abl_JJ mRNA_NN |_SYM In_IN contrast_NN to_TO phosphate_NN and_CC phosphorothioate_NN oligonucleotides_NNS ,_, antisense_NN PNAs_NNS do_VBP not_RB induce_VB degradation_NN of_IN PNA_NP --_: RNA_NP complexes_NNS by_IN RNase_NP H_NP ._SENT Despite_IN this_DT ,_, it_PP has_VBZ been_VBN found_VBN that_IN antisense_NN PNA_NP depressed_VBD the_DT amount_NN of_IN mRNA_NN coding_VBG for_IN prepro-oxytocin_NN in_IN neurons_NNS ._SENT We_PP therefore_RB measured_VBD the_DT relative_JJ level_NN of_IN bcr_NN /abl_NN mRNA_NN from_IN PNA-treated_JJ KYO-1_NP cells_NNS following_VBG a_DT competitive_JJ PCR_NP strategy_NN as_RB previously_RB described_VBD (_( ,_, )_) ._SENT The_DT total_JJ RNA_NP extracted_VBD from_IN a_DT nearly_RB 1:1_CD mixture_NN of_IN PNA-treated_JJ KYO-1_NP cells_NNS (_( containing_VBG the_DT target_NN b2a2_NN junction_NN )_) and_CC untreated_JJ K562_NP cells_NNS (_( containing_VBG a_DT b3a2_JJ junction_NN which_WDT is_VBZ not_RB recognised_VBN by_IN the_DT PNA_NP ,_, competitor_NN )_) was_VBD transformed_VBN into_IN cDNA_NN and_CC amplified_VBN by_IN PCR_NP ._SENT Target_NN and_CC competitor_NN mRNA_NN share_NN the_DT primer_JJR recognition_NN sites_NNS ,_, but_CC differ_VBP in_IN size_NN by_IN 74_CD bp_NN ._SENT Running_VBG the_DT RT_NP --_: PCR_NP products_NNS in_IN a_DT polyacryalmide_NN gel_NN ,_, two_CD bands_NNS were_VBD obtained_VBN :_: one_CD of_IN 388_CD bp_NN from_IN K562_NP ,_, the_DT other_JJ of_IN 314_CD bp_NN from_IN KYO-1_NP cells_NNS ._SENT The_DT ratio_NN between_IN b2a2_JJ mRNA_NN from_IN PNA-treated_JJ KYO-1_NP cells_NNS (_( 314_CD bp_NN )_) and_CC b3a2_JJ mRNA_NN from_IN untreated_JJ K562_NP cells_NNS (_( 388_CD bp_NN )_) provides_VBZ an_DT estimate_NN of_IN the_DT relative_JJ amount_NN of_IN target_NN mRNA_NN compared_VBN to_TO the_DT control_NN mRNA_NN from_IN untreated_JJ cells_NNS ._SENT In_IN the_DT presence_NN of_IN 10_CD microM_NN asPNA_NN ,_, the_DT b2a2_JJ /b3a2_NN ratio_NN was_VBD reduced_VBN to_TO 20_CD +-_NN 5_CD %_NN of_IN the_DT control_NN ,_, while_IN 10_CD microM_NP NLS-asPNA_NP reduced_VBD the_DT b2a2_JJ /b3a2_JJ ratio_NN to_TO only_RB 60_CD +-_NN 10_CD %_NN of_IN the_DT control_NN ._SENT The_DT efficiency_NN of_IN the_DT RT_NP reaction_NN in_IN each_DT reaction_NN tube_NN was_VBD checked_VBN by_IN amplifying_VBG a_DT 128_CD bp_NN fragment_NN of_IN abl_NN ._SENT Depression_NN of_IN p210BCR_NN /ABL_NN level_NN by_IN antisense_NN PNA_NP |_SYM The_DT capacity_NN of_IN antisense_NN PNA_NP to_TO reduce_VB the_DT expression_NN of_IN bcr_NN /abl_NN in_IN KYO-1_NP cells_NNS was_VBD measured_VBN by_IN immunoblotting_NN ._SENT KYO-1_JJ cells_NNS were_VBD cultured_VBN in_IN the_DT absence_NN and_CC presence_NN of_IN antisense_NN or_CC control_NN PNAs_NNS for_IN 24_CD ,_, 48_CD and_CC 72_CD h._NN After_IN incubation_NN ,_, the_DT amount_NN of_IN protein_NN in_IN untreated_JJ and_CC PNA-treated_JJ KYO-1_NP cells_NNS was_VBD determined_VBN by_IN western_JJ blot_NN using_VBG an_DT anti-BCR_NN /ABL_NN monoclonal_NN antibody_NN ._SENT To_TO demonstrate_VB gene_NN specificity_NN ,_, the_DT level_NN of_IN beta-actin_NN was_VBD also_RB measured_VBN in_IN all_PDT the_DT samples_NNS ._SENT Figure_NN shows_VBZ typical_JJ western_JJ blots_NNS at_IN 48_CD h._NN It_PP can_MD be_VB noted_VBN that_IN after_IN 48_CD h_NN incubation_NN with_IN 10_CD microM_NN asPNA_NN the_DT level_NN of_IN p210BCR_NN /ABL_NN protein_NN is_VBZ reduced_VBN to_TO similar35_JJ %_NN compared_VBN to_TO that_DT in_IN untreated_JJ cells_NNS ._SENT Western_JJ blots_NNS were_VBD also_RB carried_VBN out_RP at_IN 24_CD h_NN and_CC the_DT level_NN of_IN p210BCR_NN /ABL_NN compared_VBN to_TO that_DT of_IN untreated_JJ cells_NNS is_VBZ reported_VBN in_IN the_DT enclosed_VBN histograms_NNS ._SENT It_PP can_MD be_VB seen_VBN that_IN the_DT maximum_JJ reduction_NN of_IN p210BCR_NN /ABL_NN level_NN is_VBZ observed_VBN in_IN the_DT cells_NNS exposed_VBN to_TO asPNA_NN for_IN 48_CD h._NN The_DT data_NNS show_VBP that_IN 10_CD microM_NP NLS-asPNA_NP induces_VBZ at_IN 48_CD h_NN an_DT inhibition_NN of_IN bcr_NN /abl_NN expression_NN much_RB lower_JJR than_IN that_DT observed_VBN with_IN asPNA_NN ._SENT An_DT antisense_NN effect_NN was_VBD also_RB observed_VBN with_IN parPNA_NN ,_, as_IN this_DT molecule_NN forms_VBZ a_DT parallel_JJ hybrid_NN with_IN the_DT mRNA_NN target_NN ._SENT However_RB ,_, as_IN parPNA_NN has_VBZ a_DT lower_JJR affinity_NN for_IN bcr_NN /abl_NN mRNA_NN ,_, it_PP promotes_VBZ a_DT weak_JJ inhibitory_JJ effect_NN at_IN the_DT times_NNS considered_VBN :_: residual_JJ p210BCR_NN /ABL_NN is_VBZ 73_CD and_CC 65_CD %_NN at_IN 24_CD and_CC 48_CD h_NN ,_, respectively_RB ._SENT We_PP also_RB observed_VBD that_IN exposing_VBG the_DT cells_NNS to_TO the_DT PNAs_NP for_IN 72_CD h_NN resulted_VBN in_IN a_DT non-significant_JJ reduction_NN of_IN the_DT level_NN of_IN p210BCR_NN /ABL_NN (_( not_RB shown_VBN )_) ._SENT Antiproliferative_JJ effect_NN of_IN antisense_NN PNA_NP |_SYM The_DT effect_NN on_IN cell_NN growth_NN of_IN the_DT anti-b2a2_NP PNAs_NP was_VBD investigated_VBN by_IN the_DT MTT_NP assay_NN ._SENT In_IN a_DT first_JJ set_NN of_IN experiments_NNS cell_NN growth_NN was_VBD measured_VBN at_IN increasing_VBG PNA_NP concentrations_NNS ._SENT Control_NN and_CC antisense_NN PNAs_NNS were_VBD added_VBN to_TO the_DT culture_NN medium_NN at_IN 5_CD ,_, 7.5_CD or_CC 10_CD microM_NN and_CC the_DT cells_NNS were_VBD grown_VBN for_IN 72_CD h._NNS The_DT ratio_NN T_NN /C_NN between_IN treated_VBN (_( T_NN )_) and_CC untreated_JJ (_( C_NP )_) cells_NNS as_IN a_DT function_NN of_IN PNA_NP concentration_NN is_VBZ reported_VBN in_IN Figure_NP (_( top_NN )_) ._SENT It_PP can_MD be_VB seen_VBN that_IN asPNA_NN causes_VBZ a_DT strong_JJ antiproliferative_JJ effect_NN compared_VBN to_TO untreated_JJ cells_NNS (_( 26_CD ,_, 28_CD and_CC 50_CD %_NN at_IN 5_CD ,_, 7.5_CD and_CC 10_CD microM_NN ,_, respectively_RB )_) after_IN an_DT incubation_NN time_NN of_IN 72_CD h._NP NLS-asPNA_NP was_VBD found_VBN to_TO promote_VB a_DT weaker_JJR cell_NN growth_NN inhibition_NN (_( 21_CD ,_, 29_CD and_CC 28_CD %_NN )_) at_IN the_DT same_JJ concentrations_NNS ._SENT In_IN contrast_NN ,_, control_NN molecules_NNS scrPNA_NN ,_, NLS-scrPNA_NP and_CC parPNA_NP showed_VBD a_DT weak_JJ inhibitory_JJ effect_NN of_IN similar5_NN --_: 10_CD %_NN at_IN 10_CD microM_NN ._SENT The_DT effect_NN on_IN cell_NN growth_NN as_IN a_DT function_NN of_IN time_NN of_IN 10_CD microM_NP PNAs_NP is_VBZ shown_VBN in_IN Figure_NP (_( bottom_NN )_) ._SENT It_PP can_MD be_VB seen_VBN ,_, in_IN accordance_NN with_IN the_DT data_NNS in_IN Figure_NN (_( top_JJ )_) ,_, that_IN the_DT cell_NN growth_NN inhibition_NN promoted_VBN by_IN asPNA_NN reaches_VBZ a_DT level_NN of_IN 50_CD %_NN at_IN 72_CD h._NN After_IN 72_CD h_NN incubation_NN ,_, NLS-asPNA_NP inhibits_VBZ cell_NN growth_NN by_IN similar25_JJ %_NN ,_, while_IN parPNA_NP produced_VBD a_DT smaller_JJR effect_NN on_IN cell_NN growth_NN ._SENT Cell_NN cycle_NN analysis_NN of_IN KYO-1_NP cells_NNS grown_VBN in_IN the_DT presence_NN of_IN antisense_NN PNA_NP |_SYM To_TO further_RBR investigate_VB the_DT biological_JJ consequences_NNS of_IN asPNA_NN in_IN KYO-1_NP cells_NNS ,_, the_DT cell_NN cycle_NN was_VBD assessed_VBN by_IN FACS_NP analysis_NN ,_, using_VBG propidium_NN iodide_NN staining_VBG of_IN the_DT DNA_NP content_NN ._SENT KYO-1_JJ cells_NNS were_VBD grown_VBN in_IN liquid_JJ culture_NN for_IN different_JJ times_NNS in_IN the_DT presence_NN of_IN 10_CD microM_NN asPNA_NN or_CC control_NN PNAs_NNS ._SENT Figure_NN shows_VBZ that_DT asPNA_NN ,_, the_DT compound_NN with_IN the_DT highest_JJS antisense_NN activity_NN ,_, produced_VBD a_DT significant_JJ effect_NN on_IN the_DT cell_NN cycle_NN ._SENT After_IN 30_CD h_NN growth_NN ,_, untreated_JJ cells_NNS or_CC cells_NNS treated_VBN with_IN parPNA_NP or_CC NLS-asPNA_NP exhibit_VBP a_DT DNA_NN content_NN between_IN 2N_JJ (_( similar47_JJ +-_NN 1_CD %_NN of_IN cells_NNS )_) and_CC 4N_JJ (_( 12_CD +-_NN 1_CD %_NN of_IN cells_NNS )_) ,_, suggesting_VBG that_IN the_DT S_NP phase_NN is_VBZ active_JJ (_( 26_CD +-_NN 2_CD %_NN cells_NNS )_) ._SENT In_IN contrast_NN ,_, the_DT cell_NN cycle_NN profile_NN of_IN the_DT cells_NNS treated_VBN with_IN asPNA_NN shows_VBZ a_DT reduction_NN in_IN the_DT G2_NP /M_NN peak_NN from_IN 12_CD +-_NN 1_CD %_NN to_TO 3.7_CD +-_NN 0.5_CD %_NN ,_, suggesting_VBG that_IN in_IN the_DT presence_NN of_IN asPNA_NN completion_NN of_IN the_DT cell_NN cycle_NN appears_VBZ inhibited_VBN ._SENT According_VBG to_TO the_DT cell_NN cycle_NN analysis_NN ,_, a_DT fraction_NN (_( 25_CD +-_NN 4_CD %_NN )_) of_IN KYO-1_NP cells_NNS treated_VBN with_IN asPNA_NP underwent_VBD apoptosis_NN ._SENT Thus_RB ,_, it_PP is_VBZ possible_JJ that_IN the_DT inhibition_NN of_IN cell_NN proliferation_NN observed_VBD with_IN the_DT MTT_NP assay_NN results_NNS from_IN the_DT fact_NN that_IN asPNA_NN induces_VBZ apoptosis_NN ._SENT Figure_NP 2_CD |_SYM Confocal_JJ microscopy_NN images_NNS of_IN PNA-treated_JJ KYO-1_NP cells_NNS fixed_VBN on_IN glass_NN slides_NNS and_CC stained_VBN with_IN propidium_NN iodide_NN ._SENT Confocal_JJ microscopy_NN images_NNS of_IN PNA-treated_JJ KYO-1_NP cells_NNS fixed_VBN on_IN glass_NN slides_NNS and_CC stained_VBN with_IN propidium_NN iodide_NN ._SENT (_( A_DT --_: D_NP )_) Cells_NP incubated_VBN for_IN 24_CD h_NN with_IN 10_CD microM_NN asPNA-FL_NN ._SENT (_( E_NP )_) xz-Planes_NNS taken_VBN at_IN the_DT level_NN of_IN the_DT arrow_NN ._SENT (_( F_NP --_: H_NP )_) Uptake_NP of_IN NLS-asPNA-FL_NP in_IN KYO-1_NP cells_NNS stained_VBN with_IN propidium_NN iodide_NN ._SENT (_( I_PP )_) xz-Sections_NNS taken_VBN at_IN the_DT level_NN of_IN the_DT arrow_NN ._SENT Experiments_NNS were_VBD performed_VBN at_IN 37C_JJ ._SENT Bar_NN 5_CD microm_NN ._SENT Figure_NP 3_CD |_SYM Confocal_JJ microscopy_NN of_IN living_VBG KYO-1_NP cells_NNS treated_VBN for_IN 12_CD h_NN with_IN asPNA-FL_NP or_CC NLS-asPNA-FL_NP and_CC stained_VBN with_IN the_DT vital_JJ dye_NN hexidium_NN iodide_NN ._SENT Confocal_JJ microscopy_NN of_IN living_VBG KYO-1_NP cells_NNS treated_VBN for_IN 12_CD h_NN with_IN asPNA-FL_NP or_CC NLS-asPNA-FL_NP and_CC stained_VBN with_IN the_DT vital_JJ dye_NN hexidium_NN iodide_NN ._SENT (_( Top_JJ )_) Uptake_NN at_IN 37C_JJ by_IN KYO-1_NP cells_NNS treated_VBN with_IN 10_CD microM_NN asPNA-FL_NN ._SENT (_( Bottom_NN )_) Uptake_NP by_IN KYO-1_NP cells_NNS treated_VBN with_IN 10_CD microM_NN NLS-asPNA-FL_NN ._SENT Bar_NN 5_CD microm_NN ._SENT Scheme_NN 1_CD ._SENT Scheme_NN 1_CD ._SENT Figure_NP 4_CD |_SYM In_IN vitro_NN inhibition_NN of_IN reverse_JJ transcription_NN by_IN PNA_NP ._SENT In_IN vitro_NN inhibition_NN of_IN reverse_JJ transcription_NN by_IN PNA_NP ._SENT Total_NP RNA_NP extracted_VBD from_IN KYO-1_NP (_( b2a2_JJ junction_NN )_) cells_NNS was_VBD incubated_VBN overnight_RB with_IN control_NN or_CC antisense_NN PNAs_NNS at_IN increasing_JJ concentrations_NNS (_( 0_CD --_: 50_CD nM_NN )_) ._SENT The_DT RNA_NP samples_NNS were_VBD subjected_VBN to_TO RT_NP --_: PCR_NP ,_, using_VBG bcr_NN /abl_NN primers_NNS EA122_NP and_CC EA500_NP ,_, and_CC the_DT products_NNS separated_VBN in_IN a_DT 12_CD %_NN polyacrylamide_NN gel_NN ._SENT The_DT cDNA_NN amplification_NN with_IN primers_NNS EA122_NP and_CC EA500_NP provides_VBZ a_DT 314_CD bp_NN band_NN ._SENT RT_NP --_: PCR_NP is_VBZ inhibited_VBN by_IN asPNA_NN and_CC parPNA_NN ,_, which_WDT bind_VBP to_TO RNA_NP and_CC block_VB reverse_JJ transcription_NN ,_, but_CC not_RB srcPNA_NN ,_, which_WDT does_VBZ not_RB bind_VB to_TO RNA_NP ._SENT As_IN a_DT control_NN ,_, the_DT amplification_NN of_IN a_DT 128_CD bp_NN DNA_NN fragment_NN of_IN the_DT abl_NN gene_NN was_VBD amplified_VBN ._SENT Figure_NP 5_CD |_SYM Effect_NN of_IN b2a2_JJ antisense_NN PNA_NP on_IN the_DT level_NN of_IN bcr_NN /abl_NN mRNA_NN in_IN KYO-1_NP cells_NNS quantified_VBN by_IN RT_NP --_: PCR_NP ._SENT Effect_NN of_IN b2a2_JJ antisense_NN PNA_NP on_IN the_DT level_NN of_IN bcr_NN /abl_NN mRNA_NN in_IN KYO-1_NP cells_NNS quantified_VBN by_IN RT_NP --_: PCR_NP ._SENT The_DT RNA_NP from_IN an_DT equal_JJ number_NN of_IN PNA-untreated_NP K562_NP (_( competitor_NN )_) and_CC PNA-treated_NP KYO-1_NP cells_NNS was_VBD extracted_VBN ._SENT The_DT extracted_VBN RNA_NP was_VBD subjected_VBN to_TO RT_NP --_: PCR_NP ._SENT Using_VBG primers_NNS EA122_NP and_CC EA500_NP ,_, two_CD amplified_VBN bcr_NN /abl_NN bands_NNS of_IN 388_CD and_CC 314_CD bp_NN were_VBD obtained_VBN from_IN K562_NP (_( b3a2_JJ junction_NN )_) and_CC KYO-1_NP cells_NNS (_( b2a2_JJ junction_NN )_) ,_, respectively_RB ._SENT When_WRB the_DT KYO-1_NP cells_NNS were_VBD treated_VBN with_IN asPNA_NP or_CC NLS-asPNA_NP ,_, the_DT intensity_NN of_IN the_DT 314_CD bp_NN band_NN ,_, but_CC not_RB that_IN of_IN the_DT 388_CD bp_NN band_NN ,_, was_VBD reduced_VBN ,_, compared_VBN to_TO the_DT band_NN obtained_VBN by_IN treating_VBG KYO-1_NP cells_NNS with_IN scrPNA_NN ,_, a_DT control_NN PNA_NN which_WDT is_VBZ unable_JJ to_TO bind_VB to_TO bcr_NN /abl_NN mRNA_NN ._SENT As_IN a_DT control_NN we_PP also_RB amplified_VBD a_DT 128_CD bp_NN DNA_NN fragment_NN of_IN abl_NN in_IN each_DT reaction_NN tube_NN ,_, using_VBG primers_NNS ABL1A_NP and_CC EA500_NP ._SENT As_IN expected_VBN ,_, this_DT amplification_NN is_VBZ not_RB influenced_VBN by_IN PNA_NP ._SENT Figure_NP 6_CD |_SYM Immunoblot_NN of_IN KYO-1_NP cell_NN lysates_NNS using_VBG anti-ABL_NN and_CC anti-beta-actin_NN monoclonal_NN antibodies_NNS ._SENT Immunoblot_NP of_IN KYO-1_NP cell_NN lysates_NNS using_VBG anti-ABL_NN and_CC anti-beta-actin_NN monoclonal_NN antibodies_NNS ._SENT KYO-1_JJ cells_NNS were_VBD incubated_VBN with_IN 10_CD microM_NN anti_JJ sense_NN or_CC control_NN PNAs_NNS and_CC the_DT amount_NN of_IN protein_NN p210BCR_NN /ABL_NN was_VBD evaluated_VBN by_IN western_JJ blot_NN analysis_NN ,_, after_IN the_DT cells_NNS were_VBD exposed_VBN to_TO the_DT PNAs_NP for_IN 24_CD and_CC 48_CD h._NNS The_DT level_NN of_IN beta-actin_NN in_IN the_DT PNA-treated_JJ cells_NNS was_VBD also_RB measured_VBN ._SENT A_DT typical_JJ western_JJ blot_NN analysis_NN of_IN cell_NN lysates_NNS at_IN 48_CD h_NN after_IN PNA_NP treatment_NN is_VBZ shown_VBN in_IN the_DT figure_NN ._SENT The_DT levels_NNS of_IN p210BCR_NN /ABL_NN in_IN lysates_NNS obtained_VBN from_IN KYO-1_NP cells_NNS treated_VBN with_IN antisense_NN and_CC control_NN PNAs_NNS at_IN 24_CD and_CC 48_CD h_NN are_VBP shown_VBN in_IN the_DT enclosed_VBN histograms_NNS ._SENT The_DT ordinate_NN reports_VBZ the_DT residual_JJ BCR_NP /ABL_NN protein_NN expressed_VBN as_IN percent_NN T_NN /C_NN ,_, where_WRB T_NN is_VBZ the_DT p210BCR_NN /ABL_NN /beta-actin_NN ratio_NN of_IN PNA-treated_JJ cells_NNS and_CC C_NP is_VBZ the_DT p210BCR_NN /ABL_NN /beta-actin_NN ratio_NN of_IN PNA-untreated_JJ cells_NNS ._SENT The_DT uncertainty_NN on_IN each_DT value_NN is_VBZ at_IN most_JJS 20_CD %_NN ._SENT Figure_NP 7_CD |_SYM Antisense_JJ PNA_NP inhibits_VBZ the_DT proliferation_NN of_IN KYO-1_NP cells_NNS in_IN liquid_JJ culture_NN ._SENT Antisense_NN PNA_NP inhibits_VBZ the_DT proliferation_NN of_IN KYO-1_NP cells_NNS in_IN liquid_JJ culture_NN ._SENT (_( Top_JJ )_) Cell_JJ growth_NN in_IN the_DT presence_NN of_IN increasing_VBG PNA_NP concentrations_NNS ._SENT The_DT cells_NNS were_VBD grown_VBN for_IN 72_CD h_NN in_IN the_DT presence_NN of_IN the_DT indicated_JJ PNAs_NP ,_, before_IN a_DT standard_JJ MTT_NP assay_NN was_VBD performed_VBN ._SENT (_( Bottom_JJ )_) Cell_JJ growth_NN as_IN a_DT function_NN of_IN time_NN in_IN the_DT presence_NN of_IN 10_CD microM_NP PNA_NP ,_, measured_VBN by_IN MTT_NP assay_NN ._SENT The_DT data_NNS are_VBP reported_VBN as_IN T_NN /C_NN (_( OD_NN of_IN PNA-treated_JJ cells_NNS /OD_NN of_IN PNA_NP 